News & Updates

Use of aspirin at 100 mg per day proved unsuccessful at reducing the incidence of age-related macular degeneration (AMD) in a large cohort of older healthy individuals, according to medium-term data from the AMD substudy of the Aspirin in Reducing Events in the Elderly (ASPREE) trial.

In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.